Quipt Home Medical Corp.
Quipt Home Medical Corp. (QIPT.TO) Financial Performance & Income Statement Overview
Analyze Quipt Home Medical Corp. (QIPT.TO) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Quipt Home Medical Corp. (QIPT.TO) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Quipt Home Medical Corp. QIPT.TO financial performance.
Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
---|---|---|---|---|
Revenue | $61.38M | $52.63M | $63.97M | $63.95M |
Cost of Revenue | $17.77M | $17.66M | $16.69M | $16.67M |
Gross Profit | $43.61M | $34.97M | $47.27M | $47.28M |
Gross Profit Ratio | $0.71 | $0.66 | $0.74 | $0.74 |
R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
SG&A Expenses | $23.19M | $24.06M | $23.29M | $24.002M |
Operating Expenses | $43.17M | $36.80M | $46.88M | $42.87M |
Total Costs & Expenses | $60.93M | $54.47M | $63.58M | $59.54M |
Interest Income | $154000.00 | $206000.00 | -$560000.00 | $0.00 |
Interest Expense | $3.30M | $7.41M | $1.89M | $0.00 |
Depreciation & Amortization | $12.53M | $13.78M | $12.46M | $11.97M |
EBITDA | $14.78M | $17.70M | $12.65M | $16.39M |
EBITDA Ratio | $0.24 | $0.34 | $0.20 | $0.26 |
Operating Income | $448000.00 | -$1.84M | $390000.00 | $1.19M |
Operating Income Ratio | $0.007 | -$0.03 | $0.006 | $0.02 |
Other Income/Expenses (Net) | -$1.50M | -$1.65M | -$2.09M | -$3.008M |
Income Before Tax | -$1.05M | -$3.48M | -$1.70M | -$1.10M |
Income Before Tax Ratio | -$0.02 | -$0.07 | -$0.03 | -$0.02 |
Income Tax Expense | $30000.00 | -$374000.00 | $0.00 | $263000.00 |
Net Income | -$1.08M | -$3.11M | -$1.70M | -$1.36M |
Net Income Ratio | -$0.02 | -$0.06 | -$0.03 | -$0.02 |
EPS | -$0.03 | -$0.07 | -$0.04 | -$0.03 |
Diluted EPS | -$0.03 | -$0.07 | -$0.04 | -$0.03 |
Weighted Avg Shares Outstanding | $42.62M | $42.62M | $42.62M | $42.19M |
Weighted Avg Shares Outstanding (Diluted) | $42.62M | $42.62M | $42.62M | $42.19M |
Over the past four quarters, Quipt Home Medical Corp. demonstrated steady revenue growth, increasing from $63.95M in Q2 2024 to $61.38M in Q1 2025. Operating income reached $448000.00 in Q1 2025, maintaining a consistent 1% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $14.78M, reflecting operational efficiency. Net income rose to -$1.08M, with EPS at -$0.03. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan